Quarterly Pricing Pulse — Q3 2026

AbbVie (Allergan Aesthetics) filed multiple material events across Q3, anchoring Botox and Juvéderm pricing through its Allē loyalty platform. The bellwether move: rebate and bundling incentives are now table stakes, not perks. Practices relying on list-price spreads saw compression; those locked into Allē tiers gained predictability but ceded margin flexibility. Key takeaway: AbbVie is defending market share through loyalty lock-in, not price cuts. If you're not enrolled in Allē or tracking your tier, you're leaving rebate dollars on the table and losing competitive intel on what neighbors are paying.

Evolus filed three material events in Q3 promoting Jeuveau (Newtox) + Evolus Rewards directly to medspas, signaling a deliberate undercut strategy. The message: cheaper per-unit cost + loyalty rebates to poach AbbVie volume. Early adopters report 10–15% lower cost-of-goods on Jeuveau vs. Botox, but with smaller installed-base support and fewer clinical data points. Red flag: Switching injectables mid-year disrupts patient expectations and staff muscle memory. Action: Audit your Jeuveau uptake; if volume doesn't justify the switch, negotiate harder with AbbVie rather than fragmenting your supply chain.

Galderma and Merz each advanced clinical trials for Restylane Lyft (chin augmentation) and NT 201 (platysma), signaling product confidence and market expansion. However, no pricing moves or rebate announcements accompanied these filings—a contrast to the injectable frenzy. Filler pricing remains fragmented by region and distributor, with less transparency than Botox. Implication: Filler margins are still negotiable, but the window is closing. Practices should lock in 2026–2027 filler contracts now before competitive pressure forces bundling and rebates into the filler category too.

Eli Lilly filed multiple material events on Zepbound/Mounjaro supply and compounding-rule changes; Hims & Hers escalated telehealth GLP-1 offerings; Viking Therapeutics advanced next-gen dual-agonist pipelines (VK2735). Translation: GLP-1 supply is normalizing, but compounded and telehealth alternatives are fragmenting the medspa GLP-1 market. Practices offering compounded GLP-1 face tighter FDA oversight; those offering brand-name face supply constraints and margin pressure from telehealth competitors. Strategic move: If GLP-1 is a revenue pillar, lock in supply agreements with Eli Lilly or establish telehealth partnerships now, before next-gen competitors commoditize pricing further.

The Beauty Health Company (HydraFacial), Apyx Medical (Renuvion), and Bausch Health (Solta) each filed material events, but none announced aggressive pricing or rebate programs. Instead, the signals were supply stability, M&A risk (Solta), and consumable-margin pressure on facials and body-contouring devices. HydraFacial's multiple filings suggest operational turbulence; Solta's potential spin-off raises questions about service and parts support. Caution: Device-dependent revenue streams (facials, skin tightening) are less protected than injectables. Practices should diversify device portfolios and negotiate multi-year consumable pricing before consolidation reshuffles support.

Lock in contracts now. Filler and device pricing are still negotiable; injectables are hardening around loyalty tiers. Secure 2026–2027 agreements with your top three suppliers before Q4 budget cycles close. Negotiate from data. Pull your Allē tier, Jeuveau rebate, and GLP-1 cost-of-goods reports. Use competitor pricing (Evolus, Hims) as leverage with AbbVie and Galderma. Diversify supply. Don't bet the practice on one injectable or GLP-1 source. Dual-source Botox alternatives (Jeuveau, future NT 201) and GLP-1 channels (brand, compounded, telehealth) to hedge margin compression. Monitor M&A. Bausch/Solta and Beauty Health's instability could disrupt device support mid-year; have backup device vendors identified.